Recent Updates
Recently added Catalysts

Plazomicin

Phase 1

End Stage Renal Disease | Small molecule | Nephrology |BrainsWay Ltd.|Last Updated: Mar 9, 2022

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment6

FDA Designations

No designations recorded

Clinical trial landscape

Plazomicin · 1 trial · 1 indication

Phase 1 1
NCT04699656Plazomicin Study in ESRD Patients Receiving IHDEnd Stage Renal Disease
COMPLETED6 Analytics
PHASE1COMPLETED
Plazomicin Study in ESRD Patients Receiving IHD
End Stage Renal DiseaseUnlock trial analytics

Study Endpoints

Primary Endpoints

o Maximum observed plasma drug concentration (Cmax)
30 days

Plasma PK parameter for plazomicin before and after IHD

o Time to maximum observed plasma concentration (Tmax)
30 days

Plasma PK parameter for plazomicin before and after IHD

o Area under the plasma concentration time curve from time 0 to the last measurable concentration (AUC0-t)
30 days

Plasma PK parameter for plazomicin before and after IHD

o Area under the plasma concentration time curve extrapolated to infinity (AUCinf)
30 days

Plasma PK parameter for plazomicin before and after IHD

o Terminal elimination half-life (t1/2)
30 days

Plasma PK parameter for plazomicin before and after IHD

o Total plasma clearance (CL)
30 days

Plasma PK parameter for plazomicin before and after IHD

o Volume of distribution during the terminal elimination phase (Vz)
30 days

Plasma PK parameter for plazomicin before and after IHD

o Terminal elimination rate constant (λz)
30 days

Plasma PK parameter for plazomicin before and after IHD

Secondary Endpoints

• Adverse events (AEs)
30 days
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Plazomicin InjectionEXPERIMENTALplazomicin (30-minute IV infusion at 2.5 mg/kg) single dose given before IHD and single dose given after IHD

Interventions

NameTypeDescription
Plazomicin InjectionDRUGsingle dose of plazomicin
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Male and female subjects between 18 and 75 years of age with a BMI ≥19 to ≤42 kg/m2 and weight of ≥40 kg * Pre-existing ESRD requiring in-center IHD for a minimum of 3 months on a schedule of three IHD sessions per week with the third weekly IHD session occurring at least 72 h...

Countries:United States
Unlock Eligibility Criteria